Scope and Claims Analysis of US Patent 5,908,638 (Conjugated Estrogen Powder-Coated Solids with Ethylcellulose Moisture Barrier)

US 5,908,638 is a composition-and-coating patent that targets an oral solid dosage form for peri-menopausal through post-menopausal hormonal disorders. It claims a specific internal formulation architecture (conjugated estrogens coated onto substantially inorganic-free organic excipient powders with tightly defined water content and gel/non-gel organic excipient ratios) plus an external ethylcellulose moisture barrier coating, with additional dependent claim coverage for multi-hormone layering onto tablets (including progesterone/medroxyprogesterone/testosterone families) and film/bonding parameters (polymeric film composition, solids %, surfactants, plasticizers, micronized hormone).

What is claimed in one line: a dry powder conjugated estrogen coated onto a defined gel-forming/non-gel-forming organic excipient matrix (low free water and controlled total water) in a coated tablet using an ethylcellulose moisture barrier, with optional additional hormone deposition through polymeric films.

What is US Patent 5,908,638 claiming for conjugated estrogen oral tablets?

Core independent claim (Claim 1) scope. The patent is structured so that Claim 1 captures the foundational technology and most practicing product designs must avoid at least one of the defined “must-have” parameters to fall outside the claim.

1) Dosage form and therapeutic framing

Claim 1 requires:

A solid, unit dosage form capable of oral administration
For hormonal treatment of peri-menopausal, menopausal, and post-menopausal disorders in women

This is a composition claim with therapeutic context that can still be enforced against product labels/indications (method-of-use relevance) but is primarily about formulation and coating.

2) Internal powder architecture: “powdered conjugated estrogen composition”

Claim 1 requires conjugated estrogens:

Coated onto one or more organic excipients forming a powdered conjugated estrogen composition
Substantially free of inorganic excipients
Containing about 30–70% gel-forming organic excipient and about 30–70% non-gel forming organic excipient by weight
Having less than about 2.5% free water by weight and greater than 2.5% total water by weight

This creates a dual constraint: water exists overall (total water above 2.5%) but the amount present as “free water” is limited (<2.5%). Practically, the invention is about stabilizing conjugated estrogen in a water-controlled matrix.

3) External moisture barrier: ethylcellulose

Claim 1 requires:

The solid unit dosage form is coated with a moisture barrier coating comprising ethylcellulose
The moisture barrier coating is defined more specifically in dependent Claim 7 (0.5–8.0% total weight).

So the claim requires both internal stabilization via controlled water content and external stabilization via ethylcellulose moisture barrier.

Which excipients and water-content limits matter most under Claim 1?

“Substantially free of inorganic excipients”

The claim does not specify a numeric inorganic limit. That phrase creates ambiguity that can expand enforcement. From an infringement design-around perspective, formulators may need to ensure that inorganic excipient levels fall below any threshold used in claim construction or prosecution history standards.

Gel-forming vs non-gel forming organic excipient ratio

Claim 1 uses inclusive ranges:

Gel-forming organic excipient: 30–70%
Non-gel forming organic excipient: 30–70%

Because both sum to 100% (within rounding), the effective design space is a broad mixture. Most relevant claim-limiting feature is not the ratios alone, but the gel/non-gel classification tied to the specific polymers named in dependent claims (Claims 2–3, 4–5).

Free water < 2.5% and total water > 2.5%

This is likely the key stability feature. A competitor can attempt to avoid the claim by shifting either:

total water to <= 2.5% (removing “bound” water), or
free water to >= 2.5% (creating conditions where more water is “free”).

But those shifts can destabilize conjugated estrogens and impact dissolution and shelf-life. The claim therefore forces a tradeoff.

What organic excipient mixtures are covered by dependent Claims 2–5?

Claim 2: specific gel/non-gel polymer class mix

Claim 2 narrows excipients to a mixture of:

one or more gel-forming hydroxyalkylalkylcelluloses
and hydroxyalkyl cellulose

and requires:

organic excipients constitute more than about one third by weight of the solid unit dosage form.

The claim ties the formulation to cellulose-ether families and ensures the matrix is a major component rather than a minor additive.

Claim 3: hydroxypropylmethylcellulose (HPMC) specific blend

Claim 3 requires:

gel-forming organic excipients are a mixture of hydroxypropylmethylcelluloses (HPMCs)
plus 0–33% methyl cellulose or other cellulose ether

This meaningfully narrows the “gel-forming” definition, giving the patent a clear pathway into products built on HPMC blends, which are common in oral solids.

Claim 4: non-gel forming excipient at least ~40%

Claim 4 requires:

powdered conjugated estrogen composition includes at least about 40% by weight of non-gel forming organic excipient.

This interacts with Claim 1’s 30–70% ranges and further pushes non-gel content up.

Claim 5: list of non-gel forming options

Claim 5 specifies non-gel excipient selection from:

lactose
mannitol
cellulose derivatives

This is the most practical “at-risk” restriction: if a product uses lactose or mannitol as a major non-gel component with HPMC-type gel-formers, it is within the excipient playbook.

Which conjugated estrogen actives are within the patent’s definition?

Claim 6: sodium sulfate ester set

Claim 6 specifies conjugated estrogens selected from:

sodium sulfate esters of estrone
equilin
17-α-dihydroequilin
17-β-dihydroequilin
17-α-estradiol

This is an “active definition” claim element. It is broad within conjugated estrogen families but still constrained to sulfate ester components.

Impact: any product using conjugated estrogens outside this defined set (for example, different ester forms or different hormone blends not meeting the definition) may fall outside. If the product uses standard CEE (conjugated equine estrogens) composition, it may align with this definition.

How does the ethylcellulose moisture barrier coating limit infringement risk?

Claim 7: ethylcellulose coating amount

Claim 7 specifies:

moisture barrier coating is 0.5–8.0% of total weight of the solid dosage form.

A generic designer can potentially avoid Claim 1 by:

using a moisture barrier not comprising ethylcellulose, or
using ethylcellulose but outside the 0.5–8% window (if Claim 7 is treated as limiting via dependent claim analysis).

Even if Claim 7 is not asserted, Claim 1 still requires ethylcellulose as the moisture barrier.

Moisture barrier coating as an enforceable “structure”

The claim uses “coated with a moisture barrier coating comprising ethylcellulose.” “Comprising” language generally allows other components in the barrier so long as ethylcellulose is present in the moisture barrier layer. A designing-around strategy requires removing ethylcellulose from the barrier layer rather than merely changing secondary excipients.

Tablet-specific coverage: where does the patent broaden with additional hormone deposition?

Claim 8: tablet as the unit dosage form

Claim 8 specifies:

the solid unit dosage form is a tablet.

This is a dependent form constraint. If a competitor uses other oral solids (capsules, pellets), Claim 8 limits that dependent path but not Claim 1.

Claim 9–14: optional additional hormones deposited after the moisture barrier

Claims 9–14 introduce a second platform: the moisture barrier is applied, then an additional hormone is deposited on the tablet.

Claim 9: at least one additional hormone deposited after application of the moisture barrier coat
Claim 10: hormone selected from:
- progesterone
- medroxyprogesterone
- medroxyprogesterone acetate
- testosterone
- methyltestosterone
- combinations
Claim 11: hormone bonded to tablet by a polymeric film
Claim 12: polymeric film selected from:
- hydroxypropylmethylcellulose
- ethylcellulose aqueous dispersion
Claim 13–14: two or more coatings where an outer coating comprises polymeric film and at least one additional hormone; hormone set as in Claim 10

Implication: Claim 1 already requires an ethylcellulose moisture barrier. Claims 11–12 can add ethylcellulose again in the bonding film for the additional hormone, expanding options for products that use cellulose-based polymers.

What bonding-film parameters are defined in Claims 15–20 (micronization, solids %, surfactants, plasticizers)?

Claim 15: micronized hormone

Claim 15 requires:

hormone is micronized.

Products that use non-micronized hormones in their deposited layer may be outside this dependent claim.

Claim 16: polymeric film solids content

Claim 16 requires:

polymeric film contains about 10–30% solids by weight.

This is a process/formulation parameter for film formation. It can be tested by composition and process documentation, including film casting formulation.

Claim 17–18: surfactant in polymeric film

Claim 17: polymeric film further comprises a surfactant
Claim 18: surfactant selected from polyoxyethylene (20) sorbitan monoesters:
- monolaurate
- monopalmitate
- monostearate
- monooleate
- trioleate

This is a fairly specific list. If a film uses a different surfactant class (for example, polysorbates with different EO chain length, poloxamers, bile salt surfactants), it may avoid Claim 18.

Claim 19–20: plasticizer in polymeric film

Claim 19: polymeric film further comprises a plasticizer
Claim 20: plasticizer selected from:
- dibutyl sebacate
- triethyl citrate

Again, a specific list. Plasticizer selection is a common litigation point in coated tablet patents because it is measurable and often disclosed in formulation dossiers.

How broad is the patent estate around these claims? (Practice-area map)

US 5,908,638’s claims are internally coherent and likely reflect one product family design. The patent’s practical enforcement footprint is highest in:

products using conjugated estrogens in a dry powder coated onto HPMC-type excipient matrices,
tablets (or tablet-like solids) with ethylcellulose moisture barrier layers,
combination hormone products where progesterone/MPA/testosterone family hormones are layered by polymeric film onto the moisture barrier-coated core.

The dependent claim ladder also captures common film-coating formulation variables:

micronization
film solids content
surfactant identity
plasticizer identity

This increases the number of potential “touchpoints” for infringement arguments, especially for ANDA-style challenges where generic development uses similar coating stacks and excipient classes.

What generic entry risks exist for formulations built like Claim 1?

High-risk product design profile

A competing product is at higher risk if it uses all of the following:

conjugated estrogens comprising sodium sulfate ester components enumerated in Claim 6
powder coated onto primarily organic excipient matrix, substantially free of inorganic excipients
organic excipient system dominated by HPMC or HPMC/methylcellulose blends (Claims 2–3)
lactose or mannitol as a non-gel component and non-gel content at least ~40% (Claims 4–5)
defined water profile: free water <2.5% and total water >2.5%
tablet coated with ethylcellulose moisture barrier (Claims 1 and 7)
and, if applicable, layered additional hormones with HPMC/ethylcellulose film, micronized, at ~10–30% solids with specified surfactants/plasticizers (Claims 9–20)

Common design-arounds and their claim relevance

Remove ethylcellulose from the moisture barrier layer to avoid Claim 1/7.
Change water profile out of the claimed free/total ranges, but note stability and dissolution impacts.
Use non-CEE actives outside Claim 6’s enumerated conjugated estrogen set.
Avoid HPMC/methylcellulose gel-former systems if litigated under Claims 2–3, though Claim 1 still reads on gel-forming organic excipients generally.
Swap surfactant/plasticizer away from the exact lists to avoid dependent Claims 18–20.

What patent landscape considerations matter for litigation and regulatory strategy?

This record only provides the claims text. Without the patent bibliographic data, prosecution history, and any cited references, a complete US landscape mapping (related continuations, divisionals, co-owned filings, Orange Book listings, or Paragraph IV case status) cannot be produced accurately here.

Still, for enforcement and freedom-to-operate planning, US 5,908,638 should be treated as a formulation patent with layered claim dependencies that can be asserted in stages:

Claim 1 for the core excipient-water-ethylcellulose barrier system.
Dependent claims for excipient class selection (HPMC, methylcellulose), specific non-gel excipients (lactose/mannitol/cellulose derivatives), barrier loading, and multi-hormone layering conditions (film bonding, micronization, film solids, surfactants, plasticizers).

From a business standpoint, generic entrants typically face the highest risk when their formulation matches the “fingerprint” combination of (i) CEE-coated organic powder matrix with controlled free/total water and (ii) ethylcellulose moisture barrier.

Key claim scope table (what to test in a product dossier)

Claim	Scope element that drives infringement	Product attributes to check
1	Solid oral unit dosage; peri-/meno-/post-menopausal hormonal treatment; conjugated estrogen coated on organic excipients; substantially inorganic-free; 30–70% gel-forming + 30–70% non-gel by weight; free water <2.5% and total water >2.5%; ethylcellulose moisture barrier coating	Formulation composition (gel/non-gel), water spec testing, barrier composition and coating presence
2	Organic excipients include gel-forming hydroxyalkylalkylcelluloses + hydroxyalkyl cellulose; organic excipients >1/3 w/w of solid dosage	Identify polymer classes; measure mass fraction
3	Gel-forming excipients are HPMC + 0–33% methyl cellulose/other cellulose ether	Confirm HPMC grade/blend and methyl cellulose proportion
4	Non-gel organic excipient at least ~40% w/w	Confirm non-gel fraction
5	Non-gel excipient selected from lactose, mannitol, or cellulose derivatives	Identify excipient identity
6	Conjugated estrogens = sodium sulfate esters of enumerated estrone/equilin/dihydroequilin/estradiol	Confirm active ingredient composition
7	Ethylcellulose barrier loading 0.5–8.0% w/w	Barrier coat weight percent
8	Unit dosage is a tablet	Dosage form
9	Additional hormone deposited after moisture barrier	Coating stack sequence
10	Additional hormone in progesterone/MPA etc or testosterone/methyltestosterone	Hormone identity
11	Additional hormone bonded by polymeric film	Film type used for bonding
12	Polymer film selected from HPMC or ethylcellulose aqueous dispersion	Film polymer identity
13–14	Two or more coatings with outer coating polymer film + additional hormone	Multi-coating structure
15	Hormone micronized	Particle size spec
16	Polymer film solids 10–30% w/w	Film solids formulation
17–18	Surfactant present; surfactant in specified polyoxyethylene(20) sorbitan monoester list	Surfactant identity
19–20	Plasticizer present; plasticizer is dibutyl sebacate or triethyl citrate	Plasticizer identity

Key Takeaways

US 5,908,638 is anchored on a precise excipient-water-ethylcellulose barrier formulation: conjugated estrogens coated onto a substantially inorganic-free organic excipient powder with gel/non-gel ratio limits and a controlled water profile (free water <2.5%, total water >2.5%), then protected by an ethylcellulose moisture barrier coating.
The patent’s dependent claims expand coverage to common oral solid excipient systems (HPMC and methylcellulose blends; lactose/mannitol/cellulose derivative non-gel excipients), dosage form constraints (tablet), and combination hormone products where additional hormones are layered after the moisture barrier via polymeric films.
Dependent film claims add discrete, testable parameters: micronization, polymer film solids 10–30%, and specific surfactants and plasticizers (polyoxyethylene(20) sorbitan monoesters; dibutyl sebacate or triethyl citrate).
The highest infringement risk cluster is products that match the core Claim 1 “fingerprint” plus film-layered multi-hormone architectures, especially where HPMC/ethylcellulose film stacks use the listed surfactants/plasticizers.

FAQs

How can a generic design around US 5,908,638 if it must use ethylcellulose in some layer?
Remove ethylcellulose from the specific moisture barrier coating layer claimed as the “moisture barrier coating comprising ethylcellulose,” or move coating loading outside the claimed barrier percentage while also aligning other claim elements away from the water-profile and matrix definitions.
What lab tests are most relevant to the free water vs total water limitations in Claim 1?
Water specification methods used in formulation development that separate “free” vs “total” water content, aligned to the patent’s thresholds (<2.5% free; >2.5% total), since that pair is a central claim constraint.
Do Claims 2 and 3 override Claim 1 if a product uses different gel-forming polymers?
Claims 2–3 are dependent. A product that still meets Claim 1 but uses different gel-forming organic excipients may avoid dependent claim coverage but can still face Claim 1 depending on whether its excipients satisfy the broader Claim 1 gel-forming and water-matrix definitions.
How do the additional-hormone layering claims affect risk for combination therapy products?
They add an enforcement pathway beyond the CEE core: if a product deposits progesterone/MPA/testosterone-family hormones after the ethylcellulose moisture barrier and bonds them with the specified polymeric films and film parameters, dependent claims 9–20 can be asserted.
What is the practical significance of the surfactant and plasticizer lists in Claims 18 and 20?
They constrain dependent claim infringement to products using the listed polyoxyethylene(20) sorbitan monoester surfactants and dibutyl sebacate or triethyl citrate plasticizers in the polymeric film layer.

References (APA)

No sources cited.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	401062	⤷ Start Trial
Canada	2227887	⤷ Start Trial
China	100421652	⤷ Start Trial
China	1197387	⤷ Start Trial
Germany	69637601	⤷ Start Trial
European Patent Office	0840599	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,908,638

Summary for Patent: 5,908,638